Skip Navigation


Rheumatology Advance Access originally published online on December 23, 2005
Rheumatology 2006 45(3):353-354; doi:10.1093/rheumatology/kei234
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
45/3/353-a    most recent
kei234v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Somerville, M.
Right arrow Articles by Scott, D. G. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Somerville, M.
Right arrow Articles by Scott, D. G. I.
Related Collections
Right arrow Health Economics
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

LETTER TO THE EDITOR

Maximizing the use of scarce resources: vial optimization

M. Somerville, A. Brooksby and D. G. I. Scott

Rheumatology Unit, Norfolk and Norwich University Hospital, Colney Lane, Norwich, Norfolk NR4 7UY, UK

Correspondence to: M. Somerville. E-mail: margaret.somerville@nnuh.nhs.uk

The first 10% of the full text of this article appears below.

SIR, Infliximab is licensed for the treatment of severe rheumatoid arthritis, ankylosing spondylitis and Crohn's disease. It has been shown to be effective in all three conditions. All biological therapies are costly and all rheumatology units have looked at ways of maximizing the use of these therapies whilst ensuring that eligible patients are treated. We have recently audited our practice in the use of infliximab and have found imaginative ways of reducing wastage of an expensive . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?